Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.53 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402921 | 1.00 | AGTR1 (0.53) | AGTR1HKDC1TOP2ALMNACTSL | |
| SCHEMBL3133142 | 0.91 | AGTR1 (0.67) | AGTR1HKDC1LMNACTSLCTSB | |
| SCHEMBL13522802 | 0.91 | AGTR1 (0.67) | AGTR1HKDC1LMNACTSLCTSB | |
| SCHEMBL3087162 | 0.86 | TOP2A (0.49) | TOP2ALMNANPC1RAB9AMAPT | |
| SCHEMBL31690659 | 0.86 | TOP2A (0.59) | AGTR1HKDC1TOP2ANPC1RAB9A | |
| SCHEMBL9319994 | 0.83 | TOP2A (0.70) | HKDC1TOP2ALMNARAB9ASMN1; SMN2 | |
| SCHEMBL941092 | 0.83 | TOP2A (0.70) | HKDC1TOP2ALMNARAB9ASMN1; SMN2 | |
| SCHEMBL941093 | 0.83 | TOP2A (0.70) | HKDC1TOP2ALMNARAB9ASMN1; SMN2 | |
| SCHEMBL12955842 | 0.83 | TOP2A (0.56) | AGTR1HKDC1TOP2ANPC1RAB9A | |
| SCHEMBL22229892 | 0.83 | AGTR1 (0.53) | AGTR1HKDC1TOP2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | claimed |
| US-12083105-B2 | Compositions and methods for treating adult-onset neuronal ceroid lipofuscinosis (Kufs disease) | CORNELL UNIVERSITY (US) | 2024-09-10 | — | — | US | claimed |
| WO-2023086364-A1 | COMPOSITION CONTAINING 3-HYDROXYANTHRANILIC ACID AND COMPOUNDS THAT ALTER IRON HOMEOSTASIS AND METHOD OF ITS USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-05-19 | — | — | WO | claimed |
| US-20220031738-A1 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | DYVE BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | US | claimed |
| US-20210293798-A1 | Chelator-Coated Field Effect Transistor and Devices and Methods Using Same | Autonomous Medical Devices Inc. (US) | 2021-09-23 | — | — | US | claimed |
| US-20210290602-A1 | COMPOSITIONS AND METHODS FOR TREATING ADULT-ONSET NEURONAL CEROID LIPOFUSCINOSIS (KUFS DISEASE) | UNIV CORNELL (US) | 2021-09-23 | — | — | US | claimed |
| EP-3837541-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Autonomous Medical Devices Incorporated (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210161840-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | CHEVION, MORDECHAI (IL) | 2021-06-03 | — | — | US | claimed |
| EP-3781143-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | Chevion, Mordechai (IL) | 2021-02-24 | — | — | EP | claimed |
| CN-112188890-A | Compositions and methods for treating iron overload | 莫迪凯·舍维龙 | 2021-01-05 | — | — | CN | claimed |
| WO-2020037078-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Sensor-Kinesis Corporation (US) | 2020-02-20 | — | — | WO | claimed |
| WO-2019202584-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | CHEVION MORDECHAI (IL) | 2019-10-24 | — | — | WO | claimed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | claimed |
| US-20100273847-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2010-10-28 | — | — | US | claimed |
| EP-2215052-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | The University of Sydney (AU) | 2010-08-11 | — | — | EP | claimed |
| EP-2129280-A2 | METHODS OF DIAGNOSING AND ALLEVIATING GADOLINIUM TOXICITY | Cormedix Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2009055863-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2009-05-07 | — | — | WO | claimed |
| US-20080138440-A1 | Methods of diagnosing and alleviating gadolinium toxicity | CORMEDIX INC. (US) | 2008-06-12 | — | — | US | claimed |
| WO-2008066862-A2 | METHODS OF DIAGNOSING AND ALLEVIATING GADOLINIUM TOXICITY | CORMEDIX INC. (US) | 2008-06-05 | — | — | WO | claimed |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-12083105-B2 | Compositions and methods for treating adult-onset neuronal ceroid lipofuscinosis (Kufs disease) | CORNELL UNIVERSITY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240226000-A9 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024124297-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2024-06-20 | — | — | WO | disclosed |
| US-20240148918-A1 | Loading of Alginate Microspheres | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| US-20240130962-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | AUBURN UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4301341-A1 | LOADING OF ALGINATE MICROSPHERES | Board of Regents, The University of Texas System (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117241781-A | Loading of alginate microspheres | 德克萨斯大学系统董事会 | 2023-12-15 | — | — | CN | disclosed |
| EP-4277616-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | Dyve Biosciences, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2023135330-A1 | DEOXYCYTIDINE KINASE INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4204020-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Advanced Accelerator Applications International S.A. (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-4204021-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Advanced Accelerator Applications International S.A. (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023086364-A1 | COMPOSITION CONTAINING 3-HYDROXYANTHRANILIC ACID AND COMPOUNDS THAT ALTER IRON HOMEOSTASIS AND METHOD OF ITS USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11541037-B2 | Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV) | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2023-01-03 | — | — | US | disclosed |
| WO-2022187683-A1 | LOADING OF ALGINATE MICROSPHERES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022155341-A1 | TRANSDERMAL FORMULATIONS FOR PHOSPHODIESTERASE-5 INHIBITORS | DYVE BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022155352-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-3986464-A1 | TRANSDERMAL PENETRANT FORMULATIONS | Dyve Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220105062-A1 | TRANSDERMAL PENETRANT FORMULATIONS | DYVE BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| US-20220031738-A1 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | DYVE BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210311028-A1 | ANTIBODY OR APTAMER CONJUGATED-LIPID VESICLES AND DETECTION METHODS AND MICROFLUIDICS DEVICES USING SAME | Autonomous Medical Devices Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210310044-A1 | ANTIBODY OR APTAMER CONJUGATED-POLYNUCLEOTIDES AND DETECTION METHODS AND MICROFLUIDICS DEVICES USING THE SAME | Autonomous Medical Devices Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3210017-B1 | ALKALOIDS FROM SPONGE, SCAFFOLDS FOR THE INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | UNIV KING ABDULLAH SCI & TECH (SA) | 2021-10-06 | — | — | EP | disclosed |
| US-20210293798-A1 | Chelator-Coated Field Effect Transistor and Devices and Methods Using Same | Autonomous Medical Devices Inc. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210290602-A1 | COMPOSITIONS AND METHODS FOR TREATING ADULT-ONSET NEURONAL CEROID LIPOFUSCINOSIS (KUFS DISEASE) | UNIV CORNELL (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210275676-A1 | METHOD FOR PREPARING STABILIZED METAL ION LIGAND NANOCOMPLEX AND COMPOSITIONS THEREOF | UNIV AUBURN (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3864411-A1 | ANTIBODY OR APTAMER CONJUGATED-LIPID VESICLES AND DETECTION METHODS AND MICROFLUIDICS DEVICES USING SAME | Sensor-Kinesis Corporation (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3864412-A1 | ANTIBODY OR APTAMER CONJUGATED-POLYNUCLEOTIDES AND DETECTION METHODS AND MICROFLUIDICS DEVICES USING THE SAME | Sensor-Kinesis Corporation (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3860621-A1 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | Ampersand Biopharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11045553-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | AUBURN UNIVERSITY (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3837541-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Autonomous Medical Devices Incorporated (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021116712-A1 | FUNCTIONALISED MICROBUBBLE MEDIATED CELL TAGGING | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021113411-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR VITAMINS, MINERALS AND SUPPLEMENTS | Ampersand Biopharmaceuticals, Inc. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210161840-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | CHEVION, MORDECHAI (IL) | 2021-06-03 | — | — | US | disclosed |
| EP-3781143-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | Chevion, Mordechai (IL) | 2021-02-24 | — | — | EP | disclosed |
| CN-112188890-A | Compositions and methods for treating iron overload | 莫迪凯·舍维龙 | 2021-01-05 | — | — | CN | disclosed |
| WO-2020257537-A1 | TRANSDERMAL PENETRANT FORMULATIONS | AMPERSAND BIOPHARMACEUTICALS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3727458-A1 | METHOD FOR PREPARING STABILIZED METAL ION LIGAND NANOCOMPLEX AND COMPOSITIONS THEREOF | Auburn University (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-20200230245-A1 | METHOD FOR PREPARING STABILIZED METAL ION LIGAND NANOCOMPLEX AND COMPOSITIONS THEREOF | AUBURN UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| WO-2020077304-A9 | ANTIBODY OR APTAMER CONJUGATED-LIPID VESICLES AND DETECTION METHODS AND MICROFLUIDICS DEVICES USING SAME | Sensor-Kinesis Corporation (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200188359-A1 | ALKALOIDS FROM SPONGE, SCAFFOLDS FOR THE INHIBITIION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2020-06-18 | — | — | US | disclosed |
| WO-2020073030-A1 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | Ampersand Biopharmaceuticals, Inc. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020037078-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Sensor-Kinesis Corporation (US) | 2020-02-20 | — | — | WO | disclosed |
| US-10512633-B2 | Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV) | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2019-12-24 | — | — | US | disclosed |
| WO-2019202584-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD | CHEVION MORDECHAI (IL) | 2019-10-24 | — | — | WO | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20190000850-A1 | COMBINATION CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-03 | — | — | US | disclosed |
| EP-2651447-B1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | UNIV DENMARK TECH DTU (DK) | 2018-08-29 | — | — | EP | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
| EP-3041840-B1 | RILYAZINE DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE WARNER-BABCOCK INST FOR GREEN CHEMISTRY LLC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2847163-B1 | IRON CHELATORS AS HIV-1 INHIBITORS | UNIV HOWARD (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3274344-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-20180000787-A1 | ALKALOIDS FROM SPONGE, SCAFFOLDS FOR THE INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY | 2018-01-04 | — | — | US | disclosed |
| WO-2017214680-A1 | ADAMANTANE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2017-12-21 | — | — | WO | disclosed |
| EP-3256115-A2 | COMBINATION CANCER THERAPY | The Regents of The University of California (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170266174-A1 | Compositions and Methods for Extending Lifespan | COLLABORATIVE MEDICINAL DEVELOPMENT LLC (US) | 2017-09-21 | — | — | US | disclosed |
| CN-106265616-A | (thiosemicarbazone) compound application in terms for the treatment of glioma | 中国人民解放军军事医学科学院毒物药物研究所 | 2017-01-04 | — | — | CN | disclosed |
| WO-2016151499-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016130581-A2 | COMBINATION CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-18 | — | — | WO | disclosed |
| US-9394299-B2 | Rilyazine derivatives and compositions for the treatment of cancer | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160199437-A1 | THERAPEUTIC COMPOSITIONS INCLUDING IRON CHELATORS AND USES THEREOF | STEALTH BIOTHERAPEUTICS CORP (MC) | 2016-07-14 | — | — | US | disclosed |
| EP-3041840-A1 | RILYAZINE DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Warner-Babcock Institute For Green Chemistry LLC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160158392-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2016-06-09 | — | — | US | disclosed |
| WO-2016029158-A2 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | COLLABORATIVE MEDICINAL DEVELOPMENT LLC (US) | 2016-02-25 | — | — | WO | disclosed |
| US-9226984-B2 | Entrapment of radionuclides in nanoparticle compositions | Technical University of Denmark and Rigshospitalet (DK) | 2016-01-05 | — | — | US | disclosed |
| EP-2945629-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | ONCOCHEL THERAPEUTICS LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2015074010-A2 | COMPOSITIONS AND METHODS FOR CARDIAC REGENERATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150119429-A1 | Iron Chelators as HIV-1 Inhibitors | HOWARD UNIVERSITY (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2847163-A1 | IRON CHELATORS AS HIV-1 INHIBITORS | Howard University (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2015034785-A1 | RILYAZINE DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF CANCER | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150065510-A1 | Rilyazine Derivatives and Compositions for The Treatment of Cancer | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2014173860-A1 | METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH A TUMOR TO A TREATMENT WITH A COMBINATION OF IRON UPTAKE INHIBITOR AND VITAMIN D RECEPTOR AGONIST | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014078898-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | disclosed |
| WO-2013169361-A1 | IRON CHELATORS AS HIV-1 INHIBITORS | HOWARD UNIVERSITY (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2651447-A1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | Technical University of Denmark (DK) | 2013-10-23 | — | — | EP | disclosed |
| US-20130251630-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2013-09-26 | — | — | US | disclosed |
| US-20130243741-A1 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243741-A1 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2453892-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATING CANCER | INST NAT SANTE RECH MED (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-8309583-B2 | Desferrioxamine conjugates, derivatives and analogues | THE UNIVERSITY OF SYDNEY (AU) | 2012-11-13 | — | — | US | disclosed |
| WO-2012079582-A1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2012-06-21 | — | — | WO | disclosed |
| US-20120135002-A1 | Compounds and Methods for the Treatment of Cancer | INSTITUT NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-05-31 | — | — | US | disclosed |
| EP-2453892-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2012-05-23 | — | — | EP | disclosed |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| US-7833331-B2 | Non-toxic corrosion-protection pigments based on cobalt | UNIVERSITY OF DAYTON (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100273847-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2010-10-28 | — | — | US | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2215052-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | The University of Sydney (AU) | 2010-08-11 | — | — | EP | disclosed |
| EP-2182969-A1 | A MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF | The Board of Regents of The University of Texas System (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010000008-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2010-01-07 | — | — | WO | disclosed |
| US-20090163628-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON COBALT | STURGILL JEFFREY ALLEN | 2009-06-25 | — | — | US | disclosed |
| WO-2009055863-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009026524-A1 | DELIPIDATION OF HDL USING SERUM OPACITY FACTOR TO PREVENT ATHEROSCLEROSIS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009018493-A1 | A MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7422793-B2 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-09-09 | — | — | US | disclosed |
| US-7407711-B2 | Non-toxic corrosion-protection conversion coats based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008073961-A9 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | UNIV EMORY (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008073961-A2 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080138440-A1 | Methods of diagnosing and alleviating gadolinium toxicity | CORMEDIX INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7294211-B2 | Non-toxic corrosion-protection conversion coats based on cobalt | UNIVERSITY OF DAYTON (US) | 2007-11-13 | — | — | US | disclosed |
| US-7291217-B2 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070149673-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE | STURGILL JEFFREY A | 2007-06-28 | — | — | US | disclosed |
| US-7235142-B2 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007014029-A2 | YIN YANG 1 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1472319-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004065305-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE | UNIVERSITY OF DAYTON (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040104377-A1 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON | 2004-06-03 | — | — | US | disclosed |
| US-20040020568-A1 | Non-toxic corrosion-protection conversion coats based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-02-05 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (25 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | ABCC1, SLC47A1, ABCB1 | AGTR1 1610/4885HKDC1 539/4885TOP2A 152/4885 |
| US-20200230245-A1 | METHOD FOR PREPARING STABILIZED METAL ION LIGAND NANOCOMPLEX AND COMPOSITIONS THEREOF | NSFL1C, SOD1, CLTC | AGTR1 4182/4885HKDC1 4505/4885TOP2A 2088/4885 |
| US-20100273847-A1 | DESFERRIOXAMINE CONJUGATES, DERIVATIVES AND ANALOGUES | SLC40A1, FECH, FTH1 | AGTR1 3967/4885HKDC1 2003/4885TOP2A 3652/4885 |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | AGTR1 919/4885HKDC1 767/4885TOP2A 4623/4885 |
| US-20180000787-A1 | ALKALOIDS FROM SPONGE, SCAFFOLDS FOR THE INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | SARS1, BCDIN3D, OCIAD1 | AGTR1 4360/4885HKDC1 3404/4885TOP2A 379/4885 |
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | NSFL1C, SOD1, CLTC | AGTR1 4182/4885HKDC1 4505/4885TOP2A 2088/4885 |
| US-20210290602-A1 | COMPOSITIONS AND METHODS FOR TREATING ADULT-ONSET NEURONAL CEROID LIPOFUSCINOSIS (KUFS DISEASE) | CLN6, HNRNPL, HNRNPLL | AGTR1 4711/4885HKDC1 2853/4885TOP2A 3374/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | AGTR1 204/4885HKDC1 2066/4885TOP2A 778/4885 |
| US-12083105-B2 | Compositions and methods for treating adult-onset neuronal ceroid lipofuscinosis (Kufs disease) | CLN6, HNRNPL, HNRNPLL | AGTR1 4711/4885HKDC1 2853/4885TOP2A 3374/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | AGTR1 901/4885HKDC1 705/4885TOP2A 4662/4885 |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | SNRPE, NSUN2, SNRPA | AGTR1 4691/4885HKDC1 1664/4885TOP2A 1031/4885 |
| US-20130243741-A1 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | PPOX, TFRC, GLB1 | AGTR1 3612/4885HKDC1 4431/4885TOP2A 4082/4885 |
| US-20150119429-A1 | Iron Chelators as HIV-1 Inhibitors | SLC40A1, MPST, PSAT1 | AGTR1 3762/4885HKDC1 3633/4885TOP2A 1426/4885 |
| US-20210275676-A1 | METHOD FOR PREPARING STABILIZED METAL ION LIGAND NANOCOMPLEX AND COMPOSITIONS THEREOF | NSFL1C, SOD1, CLTC | AGTR1 4182/4885HKDC1 4505/4885TOP2A 2088/4885 |
| US-20160199437-A1 | THERAPEUTIC COMPOSITIONS INCLUDING IRON CHELATORS AND USES THEREOF | HAMP, SLC40A1, ARG2 | AGTR1 1878/4885HKDC1 905/4885TOP2A 4222/4885 |
| US-20150065510-A1 | Rilyazine Derivatives and Compositions for The Treatment of Cancer | RAB35, CTSZ, RAB2A | AGTR1 1491/4885HKDC1 1351/4885TOP2A 118/4885 |
| US-11045553-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | NSFL1C, SOD1, CLTC | AGTR1 4182/4885HKDC1 4505/4885TOP2A 2088/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | AGTR1 901/4885HKDC1 705/4885TOP2A 4662/4885 |
| US-10512633-B2 | Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV) | SARS1, BCDIN3D, OCIAD1 | AGTR1 4360/4885HKDC1 3404/4885TOP2A 379/4885 |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | AGTR1 2553/4885HKDC1 402/4885TOP2A 334/4885 |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | AGTR1 901/4885HKDC1 705/4885TOP2A 4662/4885 |
| US-20190000850-A1 | COMBINATION CANCER THERAPY | TP53, MCL1, TOP2A | AGTR1 3954/4885HKDC1 206/4885TOP2A 3/4885 |
| US-11541037-B2 | Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV) | SARS1, BCDIN3D, OCIAD1 | AGTR1 4360/4885HKDC1 3404/4885TOP2A 379/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | AGTR1 258/4885HKDC1 1682/4885TOP2A 788/4885 |
| US-20200188359-A1 | ALKALOIDS FROM SPONGE, SCAFFOLDS FOR THE INHIBITIION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | DHPS, OCIAD1, BCDIN3D | AGTR1 4032/4885HKDC1 3644/4885TOP2A 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.